CORBy Calypso Research7 min read

Cencora Inc (COR) Q4 2025 Earnings Analysis

Cencora's Earnings Take a Nosedive at $85.9B

Key Takeaways

Cencora Inc (COR) reported Q4 2025 earnings with revenue of $85.9B, representing a +5.5% year-over-year change. The stock moved -8.8% on earnings day.

The bull case: Cencora’s specialty-led strategy, anchored by high-margin MSO platforms and resilient core US distribution economics, supports sustained double-digit operating income growth and rising long-term guidance despite near-term accounting and interest headwinds.

The bear case: Heavy MSO investment, higher leverage and interest expense, international volatility, and potential dilution from divestitures could cap EPS upside and expose the stock if utilization or pricing dynamics normalize or turn adverse.

Financial Highlights

  • Revenue: $85.9B (+5.5% YoY)
  • Gross Profit: $2.8B (3.3% margin, +0.5% YoY)
  • Operating Income: $1.0B (1.2% margin, +0.2% YoY)
  • Net Income: $560M
  • TTM Revenue: $325.8B

Stock Performance

  • Earnings Day Move: -8.8%
  • Year-to-Date: +8.0%
  • 1-Year Return: +49.9%
  • vs. S&P 500 (since earnings): -10.8%
  • vs. Nasdaq (since earnings): -7.4%

View live COR data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Cencora Inc's Q4 2025 earnings call:

Sustainability and Cadence of US Healthcare Solutions Operating Income Growth (Core vs. MSOs, Comps, and Headwinds)

Sentiment: Positive

"If you back out RCA, and RCA had a very good quarter, but if you back out RCA, our performance in the US was still towards the higher end of our long-term guidance range, and that's even with the headwind from the customer that we lost." — James Cleary
"If we look at the balance of the year guide that you asked about, and if we exclude RCA and exclude OneOncology, we're still solidly within that long-term guidance range of 7% to 10%... and that's in spite of the headwind that we have from the loss of the oncology customer that was acquired by a competitor." — James Cleary

Strategic Rationale, Economics, and Accounting of the MSO Platform (RCA & OneOncology)

Sentiment: Positive

"Now we have two platform MSOs who are market leaders with significant capabilities within each MSO... the clinical trial excellence that exists within RCA is something that we believe we can quickly leverage across the entire platform [and] revenue cycle management is a very strong capability... that's a value driver." — Robert Mauch
"Of course, the MSO business model is a lower revenue business model, but a really nice operating margin business model... OneOncology does not have a large impact on our revenue guidance and the growth there." — James Cleary

OneOncology Deal Structure, Below-the-Line Contributions, and Leverage/Capital Allocation

Sentiment: Positive

"We increased our ownership stake when we made the announcement today from 35% to 92%, and we're really pleased to say that the practices and management will own the remaining 8%." — James Cleary
"We expect approximately $30 million of benefit in our other income and loss line for the full year fiscal 2026, and that's primarily related to earnings from a joint venture in which UUG holds a noncontrolling stake... [and] a noncontrolling loss add back to net income also related to UUG." — James Cleary

International Segment Volatility and Confidence in Full-Year Guidance

Sentiment: Mixed

"What we saw during the first quarter in the International segment was a challenging quarter due to a timing difference for manufacturer price adjustments in a developing market country... that'll really just be a timing difference that we'll see year over year." — James Cleary
"In the international segment, we're maintaining our operating income guidance of adjusted operating income growth of 5% to 8% for the fiscal year... we expect it to pick up in the balance of the fiscal year." — James Cleary

Drug Pricing, IRA/MFN, and Protection of Economics with Manufacturers

Sentiment: Mixed

"We have terms in our contracts which indicate that we'll get into discussions with manufacturers... we were very successful in those discussions with manufacturers because of the value we provide the supply chain... able to come out of those discussions with maintaining good economics and gross profit dollars." — James Cleary
"No, we haven't seen any real changes in the markets from MFN... overall, the international business is performing, you know, within our expectations, and we expect to, you know, meet our fiscal 2026 commitments there." — Robert Mauch

Bull Case

Cencora’s specialty-led strategy, anchored by high-margin MSO platforms and resilient core US distribution economics, supports sustained double-digit operating income growth and rising long-term guidance despite near-term accounting and interest headwinds.

Bear Case

Heavy MSO investment, higher leverage and interest expense, international volatility, and potential dilution from divestitures could cap EPS upside and expose the stock if utilization or pricing dynamics normalize or turn adverse.

Looking Ahead

Investors will be closely watching Cencora Inc's next quarterly report for continued execution, particularly around sustainability and Cadence of US Healthcare Solutions Operating Income Growth (Core vs. MSOs, Comps, and Headwinds). With operating margins at 1.2%, margin trends will remain a focal point. The market's negative earnings-day reaction signals that investors need to see stronger execution, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Cencora Inc's revenue in Q4 2025?

Cencora Inc reported Q4 2025 revenue of $85.9B, representing a +5.5% year-over-year change.

Did Cencora Inc beat earnings expectations in Q4 2025?

The stock declined -8.8% on earnings day, suggesting the results fell short of market expectations. The current bull case centers on: Cencora’s specialty-led strategy, anchored by high-margin MSO platforms and resilient core US distribution economics, supports sustained double-digit operating income growth and rising long-term guidance despite near-term accounting and interest headwinds.

What is the bull case for COR stock?

The bull case for COR centers on: Cencora’s specialty-led strategy, anchored by high-margin MSO platforms and resilient core US distribution economics, supports sustained double-digit operating income growth and rising long-term guidance despite near-term accounting and interest headwinds.

What is the bear case for COR stock?

The bear case for COR centers on: Heavy MSO investment, higher leverage and interest expense, international volatility, and potential dilution from divestitures could cap EPS upside and expose the stock if utilization or pricing dynamics normalize or turn adverse.

How has COR stock performed since its Q4 2025 earnings?

COR moved -8.8% on the day of its Q4 2025 earnings report, underperforming the S&P 500 by +10.8% since earnings. Year-to-date, the stock has returned +8.0%.

Browse all 400+ earnings reports →

Learn More

Analyze COR in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Cencora Inc and 400+ other stocks, explore the full platform.

Open COR on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.